We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.11T
AUM Growth
+$49.3B
Cap. Flow
-$2.91B
Cap. Flow %
-0.26%
Top 10 Hldgs %
27.74%
Holding
3,121
New
186
Increased
817
Reduced
1,825
Closed
148

Top Buys

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$18.7B
2
AAPL icon
Apple
AAPL
+$5.48B
3
NVDA icon
NVIDIA
NVDA
+$5.33B
4
TSLA icon
Tesla
TSLA
+$4.47B
5
MSFT icon
Microsoft
MSFT
+$2.15B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$4.26B
2
META icon
Meta Platforms (Facebook)
META
+$3.3B
3
MS icon
Morgan Stanley
MS
+$2.82B
4
GPN icon
Global Payments
GPN
+$2.43B
5
PYPL icon
PayPal
PYPL
+$2B

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Healthcare 16.09%
3 Consumer Discretionary 15.79%
4 Communication Services 12.38%
5 Financials 10.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FPAY
2901
DELISTED
FlexShopper
FPAY
$65K ﹤0.01%
27,700
TONX
2902
TON Strategy Co
TONX
$155M
$65K ﹤0.01%
7
HIL
2903
DELISTED
Hill International, Inc. Common Stock
HIL
$65K ﹤0.01%
33,200
SPPI
2904
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$62K ﹤0.01%
48,651
-60,253
-55% -$108K
ATHX
2905
DELISTED
Athersys, Inc. Common Stock
ATHX
$62K ﹤0.01%
2,756
-3,304
-55% -$94.8K
PAVM icon
2906
PAVmed
PAVM
$31.9M
$61K ﹤0.01%
55
-3
-5% -$6.52K
CBUS icon
2907
Cibus
CBUS
$150M
$60K ﹤0.01%
562
RLX icon
2908
RLX Technology
RLX
$2.44B
$60K ﹤0.01%
+15,500
New +$71.5K
IMDX
2909
Insight Molecular Diagnostics
IMDX
$132M
$59K ﹤0.01%
1,354
-100
-7% -$5.75K
RGLS
2910
DELISTED
Regulus Therapeutics
RGLS
$58K ﹤0.01%
18,460
+14,650
+385% +$65.1K
OUST icon
2911
Ouster
OUST
$3.31B
$54K ﹤0.01%
+1,039
New +$67.5K
WVE icon
2912
Wave Life Sciences
WVE
$1.04B
$54K ﹤0.01%
17,182
-17,900
-51% -$74.3K
BRN icon
2913
Barnwell Industries
BRN
$13.9M
$53K ﹤0.01%
18,200
ZYNE
2914
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$52K ﹤0.01%
18,200
KG
2915
Kestrel Group
KG
$61.8M
$51K ﹤0.01%
836
-55
-6% -$3.48K
ALR
2916
DELISTED
AlerisLife Inc
ALR
$51K ﹤0.01%
17,400
CNVS icon
2917
Cineverse
CNVS
$69.9M
$47K ﹤0.01%
2,005
FLUX icon
2918
Flux Power
FLUX
$12.4M
$47K ﹤0.01%
+11,000
New +$58.5K
RNAC icon
2919
Cartesian Therapeutics
RNAC
$268M
$45K ﹤0.01%
465
-47
-9% -$5.06K
AFI
2920
DELISTED
Armstrong Flooring, Inc.
AFI
$45K ﹤0.01%
22,600
PBYI icon
2921
Puma Biotechnology
PBYI
$452M
$44K ﹤0.01%
14,368
-300
-2% -$1.3K
REI icon
2922
Ring Energy
REI
$349M
$44K ﹤0.01%
19,100
-22,800
-54% -$70.6K
UAVS icon
2923
AgEagle Aerial Systems
UAVS
$62.1M
$41K ﹤0.01%
26
-55
-68% -$133K
ATOS icon
2924
Atossa Therapeutics
ATOS
$24.6M
$40K ﹤0.01%
1,656
-180
-10% -$6.59K
WORX
2925
DELISTED
SCWORX CORP NEW
WORX
$39K ﹤0.01%
134

Similar funds

T. Rowe Price Associates's Q4 2021 Portfolio in Review

As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
  • T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
  • T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
  • T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
  • T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
  • T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.